Prosight Management, LP Cytokinetics Inc Transaction History
Prosight Management, LP
- $320 Million
- Q2 2024
A detailed history of Prosight Management, LP transactions in Cytokinetics Inc stock. As of the latest transaction made, Prosight Management, LP holds 230,000 shares of CYTK stock, worth $11.8 Million. This represents 3.89% of its overall portfolio holdings.
Number of Shares
230,000
Previous 245,000
6.12%
Holding current value
$11.8 Million
Previous $17.2 Million
27.45%
% of portfolio
3.89%
Previous 4.94%
Shares
2 transactions
Others Institutions Holding CYTK
# of Institutions
408Shares Held
126MCall Options Held
3.29MPut Options Held
2.01M-
Black Rock Inc. New York, NY14.7MShares$754 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$588 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.14MShares$418 Million0.28% of portfolio
-
Wellington Management Group LLP Boston, MA7.51MShares$386 Million0.07% of portfolio
-
State Street Corp Boston, MA6.55MShares$336 Million0.02% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.84B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...